CA2911399C - TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE - Google Patents

TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE

Info

Publication number
CA2911399C
CA2911399C CA2911399A CA2911399A CA2911399C CA 2911399 C CA2911399 C CA 2911399C CA 2911399 A CA2911399 A CA 2911399A CA 2911399 A CA2911399 A CA 2911399A CA 2911399 C CA2911399 C CA 2911399C
Authority
CA
Canada
Prior art keywords
trehalose
formulation
substantially purified
amount
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2911399A
Other languages
English (en)
French (fr)
Other versions
CA2911399A1 (en
Inventor
Dalia Megiddo
Original Assignee
Seelos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seelos Therapeutics Inc filed Critical Seelos Therapeutics Inc
Priority to CA3239805A priority Critical patent/CA3239805A1/en
Publication of CA2911399A1 publication Critical patent/CA2911399A1/en
Application granted granted Critical
Publication of CA2911399C publication Critical patent/CA2911399C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2911399A 2013-05-07 2014-05-07 TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE Active CA2911399C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3239805A CA3239805A1 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361820278P 2013-05-07 2013-05-07
US61/820,278 2013-05-07
PCT/IL2014/050411 WO2014181333A2 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3239805A Division CA3239805A1 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Publications (2)

Publication Number Publication Date
CA2911399A1 CA2911399A1 (en) 2014-11-13
CA2911399C true CA2911399C (en) 2024-09-10

Family

ID=51022384

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2911399A Active CA2911399C (en) 2013-05-07 2014-05-07 TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE
CA3239805A Pending CA3239805A1 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3239805A Pending CA3239805A1 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Country Status (14)

Country Link
US (4) US10493023B2 (enExample)
EP (2) EP2994145B1 (enExample)
JP (5) JP6837835B2 (enExample)
KR (1) KR20160009617A (enExample)
AU (5) AU2014264228A1 (enExample)
CA (2) CA2911399C (enExample)
CR (1) CR20150637A (enExample)
EA (1) EA201501054A1 (enExample)
IL (1) IL241757B (enExample)
MD (1) MD20150120A2 (enExample)
MX (1) MX2015015355A (enExample)
PE (1) PE20160012A1 (enExample)
SG (1) SG11201509030TA (enExample)
WO (1) WO2014181333A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220288096A1 (en) * 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
EA201501054A1 (ru) 2013-05-07 2016-04-29 Био Бласт Фарма Лтд. Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
US10736909B2 (en) 2016-02-08 2020-08-11 Junaxo, Inc. Use of trehalose for treatment of neurological diseases
US10512656B2 (en) 2016-04-21 2019-12-24 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
EA202090510A1 (ru) 2017-08-14 2020-06-08 Приления Ньюротерапьютикс Лтд. Способ лечения бокового амиотрофического склероза придопидином
WO2019143685A1 (en) 2018-01-16 2019-07-25 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
WO2021067243A1 (en) 2019-10-01 2021-04-08 Seelos Therapeutics, Inc. Trehalose formulations and uses thereof
JP7701931B2 (ja) * 2020-02-13 2025-07-02 プリレニア ニューロセラピューティクス リミテッド プリドピジンおよび他の活性薬剤を使用して筋萎縮性側索を治療するための併用療法
WO2022013940A1 (ja) 2020-07-14 2022-01-20 オリンパス株式会社 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体
CN116966192A (zh) * 2022-09-26 2023-10-31 西安文理学院 海藻糖在制备sca3疾病治疗药物中的应用
WO2024118797A1 (en) * 2022-11-30 2024-06-06 Seelos Therapeutics, Inc. Trehalose for treating huntington's disease

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3782404A (en) 1972-06-14 1974-01-01 Commercial Shearing Adjustable, metered, directional flow control arrangements
JPS4950521U (enExample) 1972-08-14 1974-05-02
JPS516109B2 (enExample) 1972-12-28 1976-02-25
JPS557829Y2 (enExample) 1974-07-01 1980-02-21
JPS516109A (en) 1974-07-05 1976-01-19 Toshiba Tungaloy Co Ltd Aruminaatankachitan chitsukachitankeishoketsugokin
WO1997024129A1 (en) 1995-12-27 1997-07-10 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
JP4033510B2 (ja) 1995-12-27 2008-01-16 ロート製薬株式会社 トレハロースを含有する眼科用医薬組成物
JP3455633B2 (ja) 1996-06-28 2003-10-14 味の素ファルマ株式会社 潰瘍性大腸炎の予防又は治療剤
US6440446B1 (en) 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
US6602865B1 (en) 1998-11-16 2003-08-05 Ivax Drug Research Institute, Ltd. Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JP2001302517A (ja) * 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
JP4754066B2 (ja) 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
JP4255101B2 (ja) * 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
US20050053666A1 (en) * 2002-12-31 2005-03-10 Stelios Tzannis Antibody-containing particles and compositions
EP1600143B1 (en) 2003-02-13 2019-07-10 Hayashibara Co., Ltd. SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20050100637A1 (en) * 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
EP1888095A4 (en) 2005-05-13 2009-08-26 Whitehead Biomedical Inst MODULATORS OF ALPHA-SYNUCLEIN INDUCED TOXICITY
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
CN102266274B (zh) 2005-08-11 2016-05-18 株式会社林原 胶原产生增强剂及其用途
EP1958612B1 (en) 2005-11-30 2014-07-02 The Nisshin OilliO Group, Ltd. Trehalose fatty acid ester composition
JP4950521B2 (ja) 2006-03-08 2012-06-13 公益財団法人野口研究所 トレハロース誘導体とその製造法
WO2007111214A1 (ja) 2006-03-27 2007-10-04 Otsuka Chemical Co., Ltd. トレハロース化合物および該化合物を含有する医薬
CN100571707C (zh) 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
JP5258582B2 (ja) 2007-01-31 2013-08-07 株式会社糖鎖工学研究所 トレハロース化合物、その製造方法、及び該化合物を含有する免疫賦活剤
WO2008102563A1 (ja) 2007-02-23 2008-08-28 Next21 K.K. 血管攣縮の治療剤又は予防剤
TW200848063A (en) 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
EP2214714A4 (en) * 2007-10-31 2011-01-12 Diffusion Pharmaceuticals Llc NEW CLASS OF THERAPEUTIC AGENTS THAT ENHANCE SMALL MOLECULE DELIVERY
JP2009249292A (ja) * 2008-04-01 2009-10-29 Toray Ind Inc ポリリン酸を安定化剤とするエリスロポエチン溶液製剤
WO2010008860A1 (en) * 2008-06-23 2010-01-21 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
KR101021078B1 (ko) 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
EP2567963A1 (en) 2008-10-31 2013-03-13 Otsuka Chemical Co., Ltd. Trehalose compound, method for producing same, and pharmaceutical product containing the compound
CN102438652B (zh) * 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
CA3039907C (en) 2008-12-10 2022-12-13 Wista Laboratories Ltd. 3,6-disubstituted xanthylium salts
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
JP5869882B2 (ja) 2010-03-05 2016-02-24 株式会社林原 インスリン抵抗性の予防及び／又は改善剤
PL2593131T3 (pl) 2010-06-25 2020-01-31 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
CN101914118B (zh) 2010-08-06 2012-07-04 山东大学 海藻糖衍生物及其制备方法与应用
US20140066439A1 (en) * 2010-11-10 2014-03-06 Katholieke Universiteit Leuen, K.U.Leuven R&D Osteoclast activity
US9186356B2 (en) 2011-01-08 2015-11-17 Academia Sinica Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U)
EP2721151B1 (en) 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US20130310467A1 (en) 2012-03-06 2013-11-21 The Nisshin Oillio Group, Ltd. Trehalose fatty acid ester composition
JP5432322B2 (ja) 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
US20130312784A1 (en) 2012-05-24 2013-11-28 For Your Ease Only, Inc. Cosmetic organizer
US20140032304A1 (en) 2012-07-27 2014-01-30 Google Inc. Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal
JP2014139160A (ja) 2012-12-21 2014-07-31 Masaaki Hayashibara 脳機能改善剤及び脳機能改善用食品
US20220288096A1 (en) 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
EA201501054A1 (ru) 2013-05-07 2016-04-29 Био Бласт Фарма Лтд. Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
JP6130224B2 (ja) 2013-05-27 2017-05-17 公益財団法人微生物化学研究会 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物
TWI507197B (zh) 2013-07-17 2015-11-11 Univ Nat Taiwan Normal 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途
WO2015009961A1 (en) 2013-07-19 2015-01-22 Armagen Technologies, Inc. Compositions and methods related to structures that cross the blood brain barrier
US20170354666A1 (en) 2014-11-19 2017-12-14 Rush University Medical Center Compositions and methods for treating lysosomal disorders
US20160303150A1 (en) 2015-04-16 2016-10-20 BioBlast Pharma Ltd. Deuterated trehalose formulations and uses thereof
WO2017136533A1 (en) 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses
US10512656B2 (en) 2016-04-21 2019-12-24 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
WO2021067243A1 (en) 2019-10-01 2021-04-08 Seelos Therapeutics, Inc. Trehalose formulations and uses thereof

Also Published As

Publication number Publication date
US20220117883A1 (en) 2022-04-21
PE20160012A1 (es) 2016-02-14
AU2025201824A1 (en) 2025-04-03
AU2019204513A1 (en) 2019-07-18
EA201501054A1 (ru) 2016-04-29
CA2911399A1 (en) 2014-11-13
JP2025087858A (ja) 2025-06-10
WO2014181333A3 (en) 2015-01-08
JP2021152032A (ja) 2021-09-30
AU2023200303A1 (en) 2023-02-23
JP2019142907A (ja) 2019-08-29
MD20150120A2 (ro) 2016-03-31
JP2016518403A (ja) 2016-06-23
US10869831B2 (en) 2020-12-22
US12239733B2 (en) 2025-03-04
HK1217300A1 (en) 2017-01-06
EP4218769A3 (en) 2023-10-18
MX2015015355A (es) 2016-07-18
AU2020277197A1 (en) 2020-12-24
AU2019204513B2 (en) 2020-09-10
IL241757B (en) 2020-05-31
AU2014264228A1 (en) 2015-11-12
SG11201509030TA (en) 2015-11-27
CR20150637A (es) 2016-04-05
JP2023040211A (ja) 2023-03-22
US20190374463A1 (en) 2019-12-12
WO2014181333A2 (en) 2014-11-13
EP4218769A2 (en) 2023-08-02
US20160120798A1 (en) 2016-05-05
US10493023B2 (en) 2019-12-03
EP2994145A2 (en) 2016-03-16
EP2994145B1 (en) 2023-01-04
US20240009113A1 (en) 2024-01-11
JP6837835B2 (ja) 2021-03-03
CA3239805A1 (en) 2014-11-13
KR20160009617A (ko) 2016-01-26

Similar Documents

Publication Publication Date Title
US12239733B2 (en) Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US10751353B2 (en) Compositions and methods for treating an aggregation disease or disorder
US20160303150A1 (en) Deuterated trehalose formulations and uses thereof
US20250241936A1 (en) Compositions and methods for treating an aggregation disease or disorder
WO2022104022A1 (en) Rapidly infusing compositions with methotrexate and treatment methods
US20230414550A1 (en) Combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation
HK1217300B (en) Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose
EP4661891A2 (en) Peptides for treating neurological disorders
JP3817122B2 (ja) 水チャンネルオープナー組成物及び眼科用医薬組成物
CN116199743A (zh) 抗焦亡多肽及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429

EEER Examination request

Effective date: 20190429